A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma

CONCLUSION: A small subset of patients lacking a response to nivolumab derive benefit from salvage nivolumab plus ipilimumab. When possible, both drugs should be given in concomitantly, rather in an adaptive fashion.PMID:37950901 | DOI:10.1093/oncolo/oyad298

Source: The Oncologist - November 11, 2023 Category: Cancer & Oncology Authors: Rana R McKay Katharina Leucht Wanling Xie Opeyemi Jegede David A Braun Michael B Atkins Marc-Oliver Grimm Toni K Choueiri Source Type: research